Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2024 08:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces Execution of Grant Award from California Institute for Regenerative Medicines (CIRM) for Clinical Development of SENTI-202

Senti Bio announced the commencement of a grant award of $8 million from the California Institute for Regenerative Medicines (CIRM).
July 01, 2024 08:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

The California Institute for Regenerative Medicines (CIRM) has awarded an $8 million grant to Senti Bio to support clinical development of SENTI-202.
May 13, 2024 08:15 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia

Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
April 30, 2024 08:05 ET | Source: Senti Biosciences, Inc.

Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)

Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.